High-mobility Group Box-1 and Endothelial Cell Angiogenic Markers in the Vitreous from Patients with Proliferative Diabetic Retinopathy

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2012 Nov 3

PMID 23118492

Citations 23

Authors

Ahmed M Abu El-Asrar

Mohd Imtiaz Nawaz

Dustan Kangave

Marwan Abouammoh

Ghulam Mohammad

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to measure the levels of high-mobility group box-1 (HMGB1) in the vitreous fluid from patients with proliferative diabetic retinopathy (PDR) and to correlate its levels with clinical disease activity and the levels of vascular endothelial growth factor (VEGF), the angiogenic cytokine granulocyte-colony-stimulating factor (G-CSF), the endothelial cell angiogenic markers soluble vascular endothelial-cadherin (sVE-cadherin), and soluble endoglin (sEng). Vitreous samples from 36 PDR and 21 nondiabetic patients were studied by enzyme-linked immunosorbent assay. HMGB1, VEGF, sVE-cadherin, and sEng levels were significantly higher in PDR patients than in nondiabetics (P = 0.008; <0.001; <0.001; 0.003, resp.). G-CSF was detected in only 3 PDR samples. In the whole study group, there was significant positive correlation between the levels of HMGB1, and sVE-cadherin (r = 0.378, P = 0.007). In PDR patients, there was significant negative correlation between the levels of sVE-cadherin and sEng (r = -0.517, P = 0.0005). Exploratory regression analysis identified significant associations between active PDR and high levels of VEGF (odds ratio = 76.4; 95% confidence interval = 6.32-923) and high levels of sEng (odds ratio = 6.01; 95% confidence interval = 1.25-29.0). Our findings suggest that HMGB1, VEGF, sVE-cadherin and sEng regulate the angiogenesis in PDR.

Citing Articles

Inflammation: The Link between Neural and Vascular Impairment in the Diabetic Retina and Therapeutic Implications.

Ramos H, Hernandez C, Simo R, Simo-Servat O Int J Mol Sci. 2023; 24(10).

PMID: 37240138 PMC: 10218195. DOI: 10.3390/ijms24108796.

Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Mason R, Minaker S, Lahaie Luna G, Bapat P, Farahvash A, Garg A Eye (Lond). 2022; .

PMID: 35672457 DOI: 10.1038/s41433-022-02127-x.

Involvement of High Mobility Group Box 1 Protein in Optic Nerve Damage in Diabetes.

Mohammad G, Kowluru R Eye Brain. 2022; 14:59-69.

PMID: 35586662 PMC: 9109986. DOI: 10.2147/EB.S352730.

Stabilization of HIF-1α in Human Retinal Endothelial Cells Modulates Expression of miRNAs and Proangiogenic Growth Factors.

Lazzara F, Trotta M, Platania C, DAmico M, Petrillo F, Galdiero M Front Pharmacol. 2020; 11:1063.

PMID: 32848728 PMC: 7396674. DOI: 10.3389/fphar.2020.01063.

The Complex Relationship between Diabetic Retinopathy and High-Mobility Group Box: A Review of Molecular Pathways and Therapeutic Strategies.

Nebbioso M, Lambiase A, Armentano M, Tucciarone G, Bonfiglio V, Plateroti R Antioxidants (Basel). 2020; 9(8).

PMID: 32722545 PMC: 7464385. DOI: 10.3390/antiox9080666.

References

van Beijnum J, Dings R, van der Linden E, Zwaans B, Ramaekers F, Mayo K . Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood. 2006; 108(7):2339-48. DOI: 10.1182/blood-2006-02-004291. View

Harris E, Nelson W . VE-cadherin: at the front, center, and sides of endothelial cell organization and function. Curr Opin Cell Biol. 2010; 22(5):651-8. PMC: 2948582. DOI: 10.1016/j.ceb.2010.07.006. View

Abu El-Asrar A, Van den Steen P, Al-Amro S, Missotten L, Opdenakker G, Geboes K . Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. Int Ophthalmol. 2007; 27(1):11-22. DOI: 10.1007/s10792-007-9053-x. View

Chavakis E, Hain A, Vinci M, Carmona G, Bianchi M, Vajkoczy P . High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res. 2007; 100(2):204-12. DOI: 10.1161/01.RES.0000257774.55970.f4. View

Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer J . Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2002; 101(7):2652-60. DOI: 10.1182/blood-2002-05-1300. View

Nin J, Ferreira I, Schalkwijk C, Prins M, Chaturvedi N, Fuller J . Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Eur J Endocrinol. 2011; 166(2):325-32. DOI: 10.1530/EJE-11-0662. View

Abu El-Asrar A, Nawaz M, Kangave D, Geboes K, Ola M, Ahmad S . High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis. 2011; 17:1829-38. PMC: 3137555. View

Villasante A, Pacheco A, Pau E, Ruiz A, Pellicer A, Garcia-Velasco J . Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Hum Reprod. 2008; 23(3):662-7. DOI: 10.1093/humrep/dem429. View

Luan Z, Zhang H, Yang P, Ma X, Zhang C, Guo R . HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells. Immunobiology. 2010; 215(12):956-62. DOI: 10.1016/j.imbio.2009.11.001. View

10.

Walshe T, Saint-Geniez M, Maharaj A, Sekiyama E, Maldonado A, DAmore P . TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One. 2009; 4(4):e5149. PMC: 2659748. DOI: 10.1371/journal.pone.0005149. View

11.

van Beijnum J, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman W, Griffioen A . Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. 2012; 32(3):363-74. DOI: 10.1038/onc.2012.49. View

12.

Villasante A, Pacheco A, Ruiz A, Pellicer A, Garcia-Velasco J . Vascular endothelial cadherin regulates vascular permeability: Implications for ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2006; 92(1):314-21. DOI: 10.1210/jc.2006-1231. View

13.

Blazquez-Medela A, Garcia-Ortiz L, Gomez-Marcos M, Recio-Rodriguez J, Sanchez-Rodriguez A, Lopez-Novoa J . Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med. 2010; 8:86. PMC: 3012013. DOI: 10.1186/1741-7015-8-86. View

14.

Habibagahi Z, Habibagahi M, Heidari M . Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet's disease. Mod Rheumatol. 2009; 20(2):154-9. DOI: 10.1007/s10165-009-0246-1. View

15.

van Beijnum J, Buurman W, Griffioen A . Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008; 11(1):91-9. DOI: 10.1007/s10456-008-9093-5. View

16.

Duff S, Li C, Garland J, Kumar S . CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003; 17(9):984-92. DOI: 10.1096/fj.02-0634rev. View

17.

Joussen A, Poulaki V, Le M, Koizumi K, Esser C, Janicki H . A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004; 18(12):1450-2. DOI: 10.1096/fj.03-1476fje. View

18.

Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S . Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol. 2005; 166(4):1259-63. PMC: 1602384. DOI: 10.1016/S0002-9440(10)62344-9. View

19.

Abu El-Asrar A, Struyf S, Kangave D, Geboes K, Van Damme J . Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw. 2006; 17(3):155-65. View

20.

Vestweber D . VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol. 2007; 28(2):223-32. DOI: 10.1161/ATVBAHA.107.158014. View